P3, N=114, Enrolling by invitation, N.N. Petrov National Medical Research Center of Oncology

This simple and reproducible method of generating D430B-ALCL spheroids to evaluate their response to Brentuximab Vedotin treatment, as here described, may provide a valuable preliminary tool for the future pre-clinical screening of patients' primary lymphoma cells or the development of novel therapies for this type of pathology and related diseases.

P=N/A, N=222, Completed, University Hospital, Bordeaux | Not yet recruiting --> Completed | Initiation date: Sep 2025 --> Feb 2025

P1/2, N=45, Completed, University of Washington | Active, not recruiting --> Completed

P2, N=48, Active, not recruiting, City of Hope Medical Center | Trial completion date: Aug 2025 --> Jul 2026

P2, N=161, Active, not recruiting, Seagen, a wholly owned subsidiary of Pfizer | Trial completion date: Dec 2029 --> Dec 2026 | Trial primary completion date: Dec 2029 --> Dec 2026

Since CD30 can be targeted with brentuximab vedotin (BV), an anti-CD30 antibody linked with monomethyl auristatin E, a tubulin toxin, it is essential to gain a deeper understanding of the functions of CD30 in HTLV-1-infected cells in order to develop effective strategies for treating and preventing ATLL. This review describes the current understanding of how CD30 impacts the development of ATLL in cells infected with HTLV-1, with a specific emphasis on the connection between CD30 and the generation of abnormal lymphocytes.

We describe the road to the discovery of the CD30 molecule and the way CD30 has contributed to more precise diagnosis and classification of lymphomas. Moreover, we address how anti-CD30 immunotherapy was developed and the impact of the anti-CD30-auristatin conjugate and anti-CD30 CAR-T cells in treating CD30-expressing lymphomas.

P2, N=20, Active, not recruiting, New York Medical College | Not yet recruiting --> Active, not recruiting

Among 11 patients who underwent allogeneic stem cell transplantation, two developed acute graft-versus-host disease; median PFS was 234 days (95% CI 168-343), compared with 180 days (95% CI 96-279) without transplantation. BV-CHP demonstrated high ORR and CRR across age groups and ATL subtypes with a manageable safety profile, supporting its potential use as a standard treatment option.

P1, N=46, Active, not recruiting, Seagen, a wholly owned subsidiary of Pfizer | Recruiting --> Active, not recruiting | N=210 --> 46

P2, N=25, Active, not recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Oct 2025 --> Oct 2027 | Recruiting --> Active, not recruiting